Summary
The prevalence and occurrence of inflammatory bowel diseases have experienced steep increase in Western countries, as well as in populations considered ‘low risks’ before. Nevertheless, currently available therapies, including anti-tumor necrosis factor-α (TNF-α) therapy, have numerous limitations and are often associated with severe adverse effects. Therefore, the research project aims at safer and effective inflammatory bowel disease therapy by proposing development of a novel multifunctional polymeric film based platforms for oral delivery of anti-TNF-α. The drug delivery system comprises of a nanoformulation encapsulating anti-TNF-α which are then entrapped into a mucoadhesive polymeric film. These mucoadhesive polymeric films are composed of second generation highly efficient mucoadhesive S-protected thiolated polymer, which are then loaded inside pH responsive capsules for site-specific delivery. The proposed system would provide enhanced therapeutic outcome by minimizing side effect via reduction of the frequency of dosing and targeted delivery of anti-TNF-α at the site of action, which would be achieved by preventing the degradation of the encapsulated biologics, prolonging the gastrointestinal retention time of the drug delivery system, increasing drug accumulation at target site and minimizing the systemic absorption. Furthermore, additional unique benefits of the proposed systems such as the biocompatibility, biodegradability, sustained drug release at targeted site, mucus penetration of the nanoformulation, and use of accessible and patient friendly oral route, can widen its biomedical applicability and explore its use in clinics and pharmaceutical industries.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/751257 |
| Start date: | 01-05-2017 |
| End date: | 30-04-2019 |
| Total budget - Public funding: | 172 800,00 Euro - 172 800,00 Euro |
Cordis data
Original description
The prevalence and occurrence of inflammatory bowel diseases have experienced steep increase in Western countries, as well as in populations considered ‘low risks’ before. Nevertheless, currently available therapies, including anti-tumor necrosis factor-α (TNF-α) therapy, have numerous limitations and are often associated with severe adverse effects. Therefore, the research project aims at safer and effective inflammatory bowel disease therapy by proposing development of a novel multifunctional polymeric film based platforms for oral delivery of anti-TNF-α. The drug delivery system comprises of a nanoformulation encapsulating anti-TNF-α which are then entrapped into a mucoadhesive polymeric film. These mucoadhesive polymeric films are composed of second generation highly efficient mucoadhesive S-protected thiolated polymer, which are then loaded inside pH responsive capsules for site-specific delivery. The proposed system would provide enhanced therapeutic outcome by minimizing side effect via reduction of the frequency of dosing and targeted delivery of anti-TNF-α at the site of action, which would be achieved by preventing the degradation of the encapsulated biologics, prolonging the gastrointestinal retention time of the drug delivery system, increasing drug accumulation at target site and minimizing the systemic absorption. Furthermore, additional unique benefits of the proposed systems such as the biocompatibility, biodegradability, sustained drug release at targeted site, mucus penetration of the nanoformulation, and use of accessible and patient friendly oral route, can widen its biomedical applicability and explore its use in clinics and pharmaceutical industries.Status
CLOSEDCall topic
MSCA-IF-2016Update Date
28-04-2024
Images
No images available.
Geographical location(s)
